GH Research PLC

NASDAQ:GHRS

Biotechnology

Healthcare
$18.25 -0.18%

-$0.04 today

Market cap
$1.25B
Beta
1.31
P/E (TTM)
-23.8
EPS (TTM)
-$0.91
52W Low $11.32High $25.94

Volume 0.46M

Average 0.23M

GHRS Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

GH Research PLCNASDAQ: GHRS

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization growth accelerates

Q1 FY2026 depreciation & amortization of $91K rose 19.7% year over year, ahead of the +12.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 3.4% from the prior quarter. Over 3 fiscal years it compounded at +92.4% a year.

Context

  • Depreciation & amortization increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +19.7% holds above the trailing-twelve-month pace of +12.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$91K+3.4% QoQ
Last fiscal yearDec 2025
$335K+6.3% YoY
LTMMar 2026
$350K+12.5% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+19.7%——
1 year+6.3%——
3-year CAGR+92.4%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
335K USD
Year-over-year change
+6.3%
4-year CAGR
+104.9%

Depreciation & Amortization vs competitors

How GHRS compares with its peers on the latest reported figures

  • GHRS's LTM Mar 2026 depreciation & amortization of $350K is the 6th highest of the 9 companies compared; the peer median is $589.5K.
  • Its year-over-year change of +12.5% is the 2nd highest of 8, against a peer median of -13.8%.
  • Over three fiscal years its annual growth of +92.4% compares with a peer median of +24.6%.
GHRS Competitors Peer median
Depreciation & Amortization for GHRS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BHVNBiohaven Ltd.LTM Jun 2026$10.67M +22.9%+92.7%—
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026$1M +7.4%+307.8%5.0%
DFTXDefinium Therapeutics, Inc.LTM Sep 2026$631K -13.8%——
ANROAlto Neuroscience, Inc.LTM Mar 2026$605K +5.0%+24.6%—
MPLTMapLight Therapeutics, Inc.LTM Mar 2026$574K -20.3%+0.2%—
GHRSGH Research PLCLTM Mar 2026$350K +12.5%+92.4%—
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026$325.5K —+443.4%—
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$59K -90.6%-29.5%—
NERVMinerva Neurosciences, Inc.LTM Jun 2026$2.72K -71.9%-13.9%—
SPTXSeaport Therapeutics, Inc. Common Stock—— ———
Peer median (excluding GHRS) $589.5K-13.8%+24.6%5.0%

Competitors are the stored peer set for GHRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue0000335K
Gross Profit0000(335K)
Gross Margin—————
Research & Development8.55M20.48M29.82M35.02M38.73M
Selling, General & Admin6.54M10.06M11.12M15M21.61M
Operating Expenses15.1M30.55M41.22M50.31M60.34M
Depreciation & Amortization19K47K315K315K335K
EBITDA(9.17M)(22.41M)(35.21M)(38.6M)(47.46M)
EBITDA Margin—————
Operating Income(15.1M)(30.55M)(41.22M)(50.31M)(60.68M)
Operating Margin—————
Interest Income9858K1.89M2.63M2.63M
Interest Expense9K—723K717K463K
Other Income / Expenses5.9M8.1M5.64M11.35M12.42M
Income Before Tax(9.2M)(22.46M)(35.59M)(38.96M)(48.26M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(9.2M)(22.46M)(35.59M)(38.96M)(48.26M)
Net Margin—————
EPS (Basic)(0.18)(0.14)(0.68)(0.75)(0.79)
EPS (Diluted)(0.18)(0.14)(0.68)(0.75)(0.79)
Weighted Avg Shares52.02M52.02M52.02M52.03M61.04M
Weighted Avg Shares (Diluted)52.02M52.02M52.02M52.03M61.04M

GH Research PLC

NASDAQ:GHRS

Intrinsic Alpha fair value

Locked

Current Price

$18.25

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.